Zura Bio is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders. Currently, Zura Bio is developing three assets which have completed Phase 1/1b studies. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880), with a goal of demonstrating their efficacy, safety, and dosing convenience in immune and inflammatory disorders. Zura Bio is headquartered in Henderson, NV with team members in the UK and USA.
Company Details
- Employees
- 50
- Founded
- -
- Address
- 1489 W Warm Springs Rd,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.zurabio.com
- Keywords
- Immunology & Inflammation.
- HQ
- Henderson, Nevada
Zura Bio Limited (Nasdaq: Zura) Questions
Zura Bio Limited (Nasdaq: Zura)'s website is http://www.zurabio.com
Zura Bio Limited (Nasdaq: Zura)'s LinkedIn profile is https://www.linkedin.com/company/zura-bio-limited
Zura Bio Limited (Nasdaq: Zura) has
50 employees.
View email and phone details for 50
employees at Zura Bio Limited (Nasdaq: Zura).
Zura Bio Limited (Nasdaq: Zura)'s industry is
Biotechnology Research
Zura Bio Limited (Nasdaq: Zura)'s top competitors are
Enterprise Therapeutics,
Orna Therapeutics,
Korro Bio, Inc.,
Pathios Therapeutics,
Kailera Therapeutics,
Izana Bioscience,
Benitec Biopharma Inc.,
Inhibikase Therapeutics, Inc.,
Renagade Therapeutics,
Tourmaline Bio.
Zura Bio Limited (Nasdaq: Zura)'s categories are Biotechnology Research
Zura Bio Limited (Nasdaq: Zura)'s founding year is 2022
